Alumis (NASDAQ: ALMS)
$4.39
(-0.7%)
-$0.03
Price as of August 14, 2025, 4:00 p.m. ET
Alumis Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Alumis Company Info
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.